Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11929761 | 0.86 | EPHX2 (0.57) | NLRP3LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5320837 | 0.85 | MDH1 (0.54) | SMN1; SMN2MEN1KMT2AMCHR1ALDH1A1 | |
| SCHEMBL11937518 | 0.84 | NLRP3 (0.59) | NLRP3MAPK8MAPK10KCNH2CACNA1C | |
| SCHEMBL11937520 | 0.83 | KDM4E (0.43) | PPARARORCKDM4EALDH1A1HPGD | |
| SCHEMBL1581301 | 0.80 | EPHX2 (0.61) | NLRP3KCNH2CACNA1CSCN5APPARA | |
| SCHEMBL27781533 | 0.80 | KDM4E (0.60) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL2063998 | 0.79 | GAA (0.69) | NLRP3MAPK8MAPK10PPARALMNA | |
| SCHEMBL5321024 | 0.77 | KDM4E (0.42) | PPARALMNAHTTSMN1; SMN2MEN1 | |
| SCHEMBL24074030 | 0.77 | LMNA (0.49) | LMNASMN1; SMN2MEN1KMT2AMAPT | |
| Methoxymethane SCHEMBL5320839 | 0.76 | MDH1 (0.53) | LMNAHTTSMN1; SMN2MCHR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455470-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD (KR) | 2013-06-04 | — | — | US | disclosed |
| US-8455470-B2 | Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases | NEUROTECH PHARMACEUTICALS CO., LTD (KR) | 2013-06-04 | — | — | US | disclosed |
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GWAG BYOUNG-JOO (KR) | 2012-08-16 | — | — | US | disclosed |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GNT PHARMA CO., LTD. (KR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | GNT PHARMA CO., LTD. (KR) | 2009-11-12 | — | — | US | disclosed |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-09-24 | — | — | US | disclosed |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | NEUROTECH PHARMACEUTICALS CO., LTD. (KR) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120209025-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | NLRP3 1126/4885MAPK8 4280/4885MAPK10 1925/4885 |
| US-20090240079-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | NLRP3 1126/4885MAPK8 4280/4885MAPK10 1925/4885 |
| US-20090281181-A1 | Pharmaceutical Composition for Treating or Preventing Degenerative and Inflammatory Diseases | ALOX12, ALOX15, ALOX15B | NLRP3 1126/4885MAPK8 4280/4885MAPK10 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.